Full-Time

Quality Control Analyst

Quality Control

Posted on 6/4/2026

Deadline 6/15/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$79k - $127.7k/yr

New Hope, PA, USA

In Person

Must be willing to travel up to 10% domestically or internationally.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor's degree and/or equivalent degree required; preferably in Science or related field.
  • A minimum four (4) years of experience in a GMP-regulated, science-related field.
  • Detailed knowledge of analytical technologies used in the QC laboratory.
  • Skilled in performing intermediate and advanced testing within the functional laboratory, using High-Performance Liquid Chromatography and/or Ultra-Performance Liquid Chromatography, using the Empower software.
  • Knowledge and understanding of current Good Manufacturing Practices related to QC laboratory.
  • Knowledge of compendial (USP, EP, JP, etc.) requirements.
  • Skilled technical writing skills.
  • Ability to manage an individual project with mentorship from supervision/management.
  • Ability to review testing documentation, daily testing, method transfer protocols.
  • Ability to read and interpret documents such as SOPs, work instructions, test methods and protocols.
  • Proficient with using Microsoft Office applications (Outlook, Excel, Word, and PowerPoint).
  • Ability to make GMP laboratory decisions both independently and with occasional mentorship from QC Supervisor.
  • Performs independent troubleshooting and root cause analysis skills. Works directly with supervision for resolution of complex issues.
  • Demonstrates a high level of efficiency and proficiency in performing analytical testing in compliance with all regulations.
  • Experience with Karl Fischer analysis preferred.
  • Experience with Dissolution apparatus and UV preferred.
  • Experience authoring Standard Operating Procedures preferred.
  • Utilize electronic systems (LIMS, MES, LES, Empower, etc.) for execution and documentation of testing preferred.
  • This position will be located in Titusville, New Jersey and may require up to 10% domestic or international travel.
Responsibilities
  • Review / Approve laboratory data in compliance with all applicable procedures, standards and GMP regulations as well as all local, state, federal and international regulations and guidelines (FDA, EPA, DEA, OSHA, etc.).
  • Maintain a safe work environment align with environmental, health, and safety regulations.
  • Demonstrate a high level of understanding of analytical test methods with ability to independently implement and troubleshoot methods where required.
  • Use electronic systems (LIMS, MES, LES, Empower, etc.) for execution and documentation of testing.
  • Complete analytical method qualification, validation, and transfer with mentorship.
  • Assist the execution of internal audits.
  • Maintain individual training completion in a compliant state.
  • Complete corrective and preventative actions (CAPA) as assigned.
  • Support investigations and resolution of laboratory nonconformances.
  • Make contributions to, and occasionally lead, continuous improvement teams. Interaction and involvement with global project teams.
  • Provide input to functional laboratory meetings and take actions as a QC representative at cross-functional meetings.
  • May occasionally assist the supervisor in prioritizing for the functional QC laboratory.
  • Support the development and execution of CREDO action plans and initiatives.
  • Trend analytical data generated by other analysts
Desired Qualifications
  • Analytical Reasoning
  • Business Behavior
  • Compliance Management
  • Controls Compliance
  • Cross-Functional Collaboration
  • Innovation
  • ISO 9001
  • Persistence and Tenacity
  • Problem Solving
  • Process Oriented
  • Quality Auditing
  • Quality Control (QC)
  • Quality Control Testing
  • Quality Standards
  • Quality Systems Documentation
  • Report Writing
  • Technologically Savvy

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Your Connections

People at Johnson & Johnson who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Firefly Bio expands J&J's KRAS-focused oncology platform for hard-to-treat tumors.
  • TREMFYA, CARVYKTI, and RYBREVANT are offsetting STELARA's biosimilar decline.
  • Jacksonville and Pennsylvania investments deepen manufacturing capacity and support future growth.

What critics are saying

  • STELARA's biosimilar erosion continues to pressure immunology revenue until replacements scale.
  • Talc litigation remains a recurring cash, reserve, and reputational overhang.
  • Firefly Bio's clinical-stage assets face efficacy risk before meaningful oncology contribution.

What makes Johnson & Johnson unique

  • J&J combines pharmaceuticals, MedTech, and consumer health across global markets.
  • Its 2026 pipeline spans oncology, immunology, neuroscience, and cardiovascular programs.
  • AAA credit and 64 straight dividend increases signal exceptional financial durability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

INACTIVE